News | Stents | February 10, 2016

CeloNova Enrolls First Patient in COBRA REDUCE Trial

Trial evaluates two-week dual antiplatelet therapy duration in patients at high risk of bleeding

CeloNova, COBRA REDUCE trial, first patient enrolled, Cobra PzF coronary stent

February 10, 2016 — CeloNova BioSciences Inc. announced this week that the first patient has been enrolled in its COBRA REDUCE trial. The COBRA REDUCE trial recently received conditional U.S. Food and Drug Administration (FDA) approval and will study the Cobra PzF nanocoated coronary stent (NCS) system in patients at high risk of bleeding.

The first stent in the trial was implanted at the Northshore University Hospital, New York by Loukas Boutis, M.D. Eventually, 844 patients will be enrolled in the clinical trial both in the United States and Europe.

Rajiv Jauhar, M.D., chief of cardiology and director cardiac catheterization labs at the Northshore University Hospital in New York, said, “We are excited to be part of this second, very important, trial with the COBRA PzF stent. We were the highest enrolling center in the initial PzF SHIELD trial with the COBRA PzF stent and hope to repeat our achievement.”

About one in five patients are at high risk of bleeding after stenting. Complications from bleeding after percutaneous coronary intervention (PCI) occur more frequently than myocardial infarctions and have a greater impact on mortality. The trial will evaluate if the Cobra PzF stent, with its novel Polyzene-F nanocoating and advanced thin-strut design, can help reduce bleeding as compared to drug eluting stents (DES), by shortening the duration of dual antiplatelet therapy (DAPT) to 14 days in patients treated with oral anticoagulation and undergoing PCI.

“For patients with high risk of bleeding such as those on triple therapy, the optimal duration of DAPT and type of stent are important questions,” said Adnan Kastrati, M.D., professor of medicine at Deutsches Herzzentrum, München, Germany and the principal investigator of the trial.

”If the COBRA PzF stent, with its novel nanocoating, is able to reduce the duration of DAPT to only two weeks and to reduce bleeding, while maintaining parity with DES in thrombosis and restenosis, it could be a very compelling new treatment option.”

The COBRA REDUCE trial is the second major interventional cardiology trial for CeloNova and follows a successful early enrollment completion of the PzF SHIELD investigational device exemption (IDE) study last year. Positive results from the PzF SHIELD study will allow the company to complete its premarket application to the FDA for the Cobra PzF stent.

These trials are part of a comprehensive clinical program studying over 2,000 patients worldwide. Previous peer-reviewed studies with over 700 patients implanted with the prior generation stent coated with the Polyzene-F nanocoating demonstrated low target lesion revascularization (TLR) and no stent thrombosis.

The Cobra PzF stent has thin struts made of cobalt chromium super alloy and is coated with an advanced Polyzene-F nanocoating, which may reduce fibrinogen and platelet adhesion as shown in preclinical studies. Furthermore, the stent platform is designed to minimize vessel wall injury and lower inflammation as demonstrated in preclinical studies.

The Cobra PzF coronary stent system is an investigational device in the United States. It received CE Mark approval in 2012 and launched in Europe and the Middle East in 2013.

For more information: www.celonova.com

Related Content

Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott While Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Overlay Init